RhumbLine Advisers’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

RhumbLine Advisers’s Portfolio DOVA Stock Details DOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-12,827	Closed	-$359K	–	2965
2019 Q3	$359K	Sell	12,827 -100	-0.8%	-$1.62K	﹤0.01%	2481
2019 Q2	$182K	Sell	12,927 -2,227	-15%	-$21.2K	﹤0.01%	2810
2019 Q1	$135K	Sell	15,154 -189	-1%	-$1.53K	﹤0.01%	2824
2018 Q4	$116K	Buy	15,343 +4,843	+46%	+$78K	﹤0.01%	2864
2018 Q3	$220K	Sell	10,500 -750	-7%	-$17.9K	﹤0.01%	2682
2018 Q2	$337K	Buy	+11,250	New	+$306K	﹤0.01%	2476

RhumbLine Advisers's DOVA Position: Q4 2019 in Review

RhumbLine Advisers sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2019, closing a stake of 12,827 shares — an estimated $359K sold.

RhumbLine Advisers first reported a position in DOVA in Q2 2018 and held it in 6 quarters. The position peaked at $359K in Q3 2019. 0 funds tracked by Wall St. Rank hold DOVA as of Q4 2019.

RhumbLine Advisers reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
RhumbLine Advisers sold 12,827 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $359K.
RhumbLine Advisers first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 6 quarters.
RhumbLine Advisers's Dova Pharmaceuticals, Inc. Common Stock position peaked at $359K in Q3 2019.
0 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on RhumbLine Advisers's 13F filing for Q4 2019, filed 5 Feb 2020.